The USA-India Chamber of Commerce mission is to provide a pro-active & professional platform for high ranking policy makers, senior business executives, academicians, and investors in the United States and India to network, facilitate and promote trade, investments & economic cooperation. USAIC’s four point agenda is: Trade, Investment, Policy and Advocacy.
US-India BioPharma & Healthcare Summit, Thursday June 23 2011
OVERVIEW
Our annual US-India BioPharma & Healthcare Summit has created an ecosystem bringing together all stakeholders: healthcare and life sciences executives, investors, policy makers and academia. 2010 Summit attracted over 300 senior executives. Our annual Summit has become THE BioPharma event in the world to learn and share for senior executives focused on Drug Discovery & Development, Licensing, Clinical Research, External Research, Healthcare, Innovation, M&A, Deal Flow and Emerging Markets. Senior policy makers from India are regular participants.
The Summit helps facilitate cross border investments, create public-private-academic partnerships and open new opportunities to take the Global BioPharma and Healthcare business to the next level.
HIGHLIGHTS
Annual high profile summit of established and emerging Biotech, Pharmaceuticals, Medical Devices, Healthcare companies, Venture Capitalists, Policy Makers and Academia from the US, Europe and India
Annual R&D spend of just the Advisory Board members in excess of $25 billion
THE Bio Pharma event in the world focused on BioPharma, Medical Devices and Healthcare
Annual summit provides continuity and results by bringing all stakeholders together
USA-India Chamber of Commerce commissioned Boston Consulting Group Position Paper (complimentary copy)
Hear about critical trends directly from the global industry thought leaders and policy makers to create your successful R&D and emerging market strategies
Learn about new models in R&D, partnering and commercial models - DIRECTLY from major implementors
Meet the top global industry thought leaders, investors, academicians and policy makers at one location
Large participation by CEOs, Chief Scientific Officers and Chief Medical Officers of BioPharma, Medical Devices and Healthcare companies
Big participation by leadership of top Medical and Public Health Schools
Highest concentration of senior level BioPharma & Healthcare executives
An ideal platform to Learn Share Network Benefit
A forum open only to senior executives
Lunch, Cocktails & High Power Networking Reception
Summit Emcee - Dr. Bill Chin, Executive Dean for Research, Harvard Medical School
Time *
Topic
9-30 AM - 10-00 AM
Registration and Networking
10-00 AM - 10-05 AM
Welcome address by Karun Rishi, President, USA-India Chamber of Commerce
10-05 AM - 10-15 AM
Opening comments by Dr. Bill Chin, Executive Dean for Research, Harvard Medical School
10-15 AM - 10-45 AM
Release of annual Position Paper.
Presentation of USA-India Chamber of Commerce commissioned annual Position Paper by Bart Janssens, Partner, The Boston Consulting Group
10-45 AM - 11-40 AM
Panel Discussion: Drug Discovery and Collaborative Research: Increasing the odds of success
Panelists:
Dr. Martin Fitchet, Chief Operating Officer, Johnson & Johnson Pharma R&D
Dr. Ivan Gergel, Executive Vice President R&D, Endo Pharmaceuticals
Dr. John Leonard, Senior Vice President- Pharmaceuticals R&D, Abbott
Sri Mosur, CEO, Global Drug Discovery & Development, Jubilant Life Sciences
Dr. Peter Mueller, Executive Vice President- Global R&D, Vertex Pharmaceuticals
Moderator:
Dr. Bill Chin, Executive Dean for Research, Harvard Medical School
11-40 AM - 11-50 AM
Break
11-50 AM - 1-15 PM
Luncheon Panel Discussion: "Show me the Money": Funding innovation, investment opportunities and cross border M&A trends in the BioPharma & Healthcare
Panelists:
Hari Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences
Honoring Dr. M.K. Bhan
Introduction by Dr. Nirmal K. Ganguly, Chairman JIPMER & ex Director General ICMR Award Presentation
Address by Dr. M.K. Bhan, Secretary, Department of Biotechnology, Govt. of India
5-25 PM - 5-30 PM
Closing remarks
5-30 PM - 7-30 PM
Cocktails & Networking Reception at the Charles View Ballroom, 16th Floor
* Speakers and Timings subject to change
Please keep your cell phones in the silent mode
Details on panel discussions
Drug Discovery and Collaborative Research: Increasing the odds of success Context: New models for drug discovery, are gaining in popularity. At the same time, older models for partnership and collaborative research between Indian companies and global companies are evolving from a discrete "fee for service" to a more integrated "pay for solution" model. Strategic partnerships/alliances are being formed across the value chain. This panel will discuss the implications of the newer models on the nature of collaboration between US and India, and the role of the key stakeholders in facilitating these partnerships.
Key issues to highlight
How is global R&D strategy evolving? Can greater collaborative R&D models help address the R&D productivity challenge?
How can India fit into this evolving strategy and how can sustainable innovation be achieved?
What needs to change to enable truly strategic partnerships and move away from a Principal-vendor relationship as it has been in the past?
Based on the learning from past partnerships, what can Indian companies leverage to provide the greatest value? Is this a sustainable value proposition?
What role should the government play in facilitating collaboration?
"Show me the Money": Funding innovation, investment opportunities and cross border M&A trends in US-India BioPharma & Healthcare Context: Investments in the bio-pharma drug discovery space have largely been driven by industry as VCs/PEs are moving away from life sciences on account of lack of returns and tightening regulations. Drug discovery models are adapting to limited availability of early stage funding through focus on limited aspects and leveraging research alliances. Acquisitions to build strength in specific areas and gain market access have been observed. This panel will focus on what Global investors like about India M&A and investment opportunities, and what they wish they could see more of.
Key issues to highlight
What are the different types of investment opportunities being evaluated by the investors? What are the big areas of opportunity that excite them?
What sort of companies will attract funding from Big Pharma? from VCs?
Is there an opportunity for more large, RBX like deals or are we leaning towards more smaller deals?
How can we make funding drug discovery initiatives in India an attractive business proposition? What are the improvement areas in current efforts?
What funding models are likely to succeed in emerging markets e.g. government funded venture capital? How can these models be improved?
What should be the role of the government in funding innovation?
What could be opportunities for Indian companies to acquire attractive assets / technologies? Is that plausible without greater external funding?
Industry-Academia Partnerships: Can they be the engine of a new wave of innovation? Context: Current models of interaction between industry and academia have not leveraged academia to the full extent possible. Globally newer models are being developed for industry-academia partnerships to improve R&D productivity. This panel will discuss ways to enhance the industry - academia partnership landscape as well as integrate Indian academia in the global R&D/healthcare landscape.
Key issues to highlight
How can knowledge, assets and best practices of different stakeholders (US and Indian industry; US and Indian academia) be leveraged most effectively?
What additional training or capacity building is required in the areas of Drug discovery, Development and Healthcare where future partnerships could be valuable?
Several academic partnerships have been formed recently, what is working well and what could be the levers to further enhance their effectiveness?
What are potential roadblocks (e.g., IP sharing issues, patent pooling for products for developing countries, access to Indian universities) are inhibiting this collaboration?
What do we believe is the future model of collaboration? Is it tri-lateral i.e. between, industry, US academia and Indian academia?
How do we enhance this tri-lateral collaboration? How can Indian academia contribute in these collaborations? What is the role that US academia and the industry stakeholders can play to facilitate this?
What are the implications for India? What are the areas that need to be addressed to benefit from this?
Diabetes management: Science, research trends and market opportunities Context:
Diabetes, with its acute and long term complications, and the myriad of disorders associated with it, is a major health hazard. With recent rapid incidence of diabetes, it is predicted that 300 million individuals worldwide will have diabetes by 2025, with a major impact on the population of developing countries like India. This panel would focus on the latest developments in the field of research, discuss a short and mid term view from the industry as well as share a perspective on the long term viewpoint from academia. Additionally, the panel would also explore trends and implications for clinical development.
Key issues to highlight
What are the latest advancements in our understanding of diabetes, especially in the field of genetics and what are the hurdles being faced?
What could be the implications for the development phase of new compounds?
What could be the possible innovations to tackle the issue of patient compliance? What examples in other disease areas can we learn from?
How will a more stringent regulatory environment impact clinical development and what do we see are the emerging strategies?
What could be the role of India in this? How can global companies benefit from increasing collaboration with Indian and other emerging market partners?
Moving the needle on Drug Development, Clinical Research and other Healthcare opportunities Context: Drug development represents 50% of the R&D cost base. Over the last decade timelines have increased and costs have sky rocketed. This is also an area where there has already been double digit growth in Indian trial volume. On that platform, this panel will investigate how we can collaborate to deliver drugs on time at lower cost without compromising on quality.
Key issues to highlight:
What are the opportunities for global BioPharma to increase the amount of clinical trial activity in India? How can India leverage the existing clinical trial activity to generate value in other parts of the value chain?
Should pharmacos and CROs develop deeper, direct relationships with mega sites and hospitals? What value would this collaboration provide?
Can partnerships between bio-pharma companies and medical (research) institutes help in developing the required capabilities? How can academic medical centers and the industry help Indian institutes foster more of these partnerships?
What support from the government can help boost the scale of clinical development in India?
What are other roadblocks and how best can we overcome them?
How can the US institutions best help the Indian healthcare and delivery system?
PARKING
Validated discounted parking is available for summit participants at Hyatt Regency Cambridge.
Please collect your discount tickets at the time of registration.
DIRECTIONS From the West From Mass Pike: Take exit 18 - Allston / Cambridge (left hand exit).
Follow the signs for Cambridge. Cross the River Street Bridge, exit right at the end of the bridge onto Memorial Drive. Hyatt is 1/2 mile up on Memorial Drive (Route 3) on the left hand side. Turn left at the traffic light to access the hotel entrance and parking garage. From the South
From I-93: Take exit 26 - Storrow Drive/Back Bay/Cambridge.
Stay in the right lane (Storrow Drive). Go 3/4 mile and take second exit on left, Government Center/Kendall Square. Go up the ramp and stay in the right lane. Turn right at the stop sign; go across the Longfellow Bridge. Take the first right off bridge and turn onto Memorial Drive (Route 3). Stay on Memorial Drive approximately 1 mile on right, at light turn right. Hyatt is on your left. From the North
From I-93 or Route 1: Take exit 26 - Storrow Drive and follow "FROM THE SOUTH" directions. From Logan International Airport
Follow signs to the Mass Turnpike: 90 Boston/Williams Tunnel. Pay toll upon exiting airport. You will be heading West on 90. From 90 West, take exit 20 Brighton/Cambridge (pay another toll). Out of the toll booth, bear right following sign for Cambridge/Somerville exit. From this exit ramp, stay straight through two lights and cross over the bridge. Just over the bridge, turn right at the light onto Memorial Drive. Stay in the left lane. Continue up/over overpass keeping in left lane. At the first light on Memorial Drive make a left and then another quick left into the Hyatt front circle.
Registration is full and closed. No walk-ins or at the door registration.
Summit open only to Senior Executives, Enterpreneurs, VCs, Investment Bankers, Private Equity Firms, Academia and Policy makers in the Life Sciences industry (Pharmaceuticals, Biotechnology, Medical Devices and Healthcare).
Restricted entry for Service firms, Sales personnel and Consultants. USA-India Chamber of Commerce reserves the right to decline any registration without assigning any reason
From Mass Pike: Take exit 18 - Allston / Cambridge (left hand exit).
